SCHEMBL6071362

SCHEMBL6071362

CCN1CCCc2cc(OC)ccc2C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 2/20 0.57
▸ WDR77 Q9BQA1 2/20 0.57
▸ DRD3 P35462 5/20 0.56
▸ DRD2 P14416 2/20 0.56
▸ DRD4 P21917 2/20 0.56
▸ ROCK2 O75116 1/20 0.47
▸ MPO P05164 1/20 0.47
▸ CYP24A1 Q07973 2/20 0.45
▸ CYP27A1 Q02318 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ ADAM17 P78536 1/20 0.45
▸ TNIK Q9UKE5 1/20 0.45
▸ ITGB3 P05106 1/20 0.44
▸ ITGA2B P08514 1/20 0.44
▸ DRD1 P21728 1/20 0.44
▸ DRD5 P21918 1/20 0.44
▸ HTR2A P28223 1/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL471627 0.92 PRMT5 (0.51) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL29438671 0.92 PRMT5 (0.51) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL19852196 0.85 PRMT5 (0.60) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL5946719 0.82 PRMT5 (0.52) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL23190427 0.82 PRMT5 (0.52) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL20214501 0.81 MEN1 (0.51) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL6071228 0.80 PRMT5 (0.55) PRMT5WDR77DRD3DRD2DRD4
SCHEMBL24892629 0.80 DRD2 (0.58) DRD3DRD2DRD4ADAM17DRD1
SCHEMBL12061308 0.80 HRH3 (0.62) DRD3DRD2DRD4HSD17B10DRD1
SCHEMBL21845054 0.80 AOC3 (0.49) PRMT5WDR77ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089347-A1 Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2006-04-27 — — US disclosed
EP-1539704-A1 SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-06-15 — — EP disclosed
WO-2004018432-A1 SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2004-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089347-A1 Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses HRH3, HRH4, HRH2 PRMT5 270/4885WDR77 266/4885DRD3 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback